FY2025 Earnings Forecast for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Investment analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for Bruker in a research report issued on Tuesday, March 11th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $2.68 for the year, up from their prior forecast of $2.67. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share.

Several other research firms also recently weighed in on BRKR. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a research report on Thursday, December 5th. Stifel Nicolaus reduced their target price on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research report on Friday, February 14th. Guggenheim reiterated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Barclays reduced their target price on Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Finally, UBS Group initiated coverage on Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price on the stock. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $70.50.

Bruker Stock Performance

NASDAQ BRKR opened at $45.97 on Friday. The business’s 50-day moving average price is $53.66 and its 200 day moving average price is $58.40. Bruker has a twelve month low of $44.11 and a twelve month high of $94.86. The company has a market capitalization of $6.97 billion, a PE ratio of 60.49, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently modified their holdings of the stock. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bruker during the 4th quarter valued at about $234,000. EDENTREE ASSET MANAGEMENT Ltd grew its stake in Bruker by 11.2% during the 4th quarter. EDENTREE ASSET MANAGEMENT Ltd now owns 158,000 shares of the medical research company’s stock valued at $9,262,000 after purchasing an additional 15,900 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Bruker by 17.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 356,969 shares of the medical research company’s stock valued at $20,926,000 after purchasing an additional 52,214 shares in the last quarter. Voloridge Investment Management LLC grew its stake in Bruker by 179.6% during the 4th quarter. Voloridge Investment Management LLC now owns 18,906 shares of the medical research company’s stock valued at $1,108,000 after purchasing an additional 12,145 shares in the last quarter. Finally, Two Sigma Advisers LP grew its stake in Bruker by 406.1% during the 4th quarter. Two Sigma Advisers LP now owns 140,700 shares of the medical research company’s stock valued at $8,248,000 after purchasing an additional 112,900 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, March 17th. This represents a $0.20 annualized dividend and a dividend yield of 0.44%. Bruker’s payout ratio is currently 26.32%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.